Abstract
Although meningococcal disease caused by serogroup B remains an important public health concern, a licensed vaccine providing broad protection against this pathogen is not yet available. Advances in genomics have paved the way for the discovery of new vaccine candidates for inclusion into a multicomponent serogroup B vaccine. In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB.
MeSH terms
-
Antibodies, Bacterial / blood
-
Antigens, Bacterial / genetics
-
Antigens, Bacterial / immunology*
-
Blood Bactericidal Activity
-
Cell-Derived Microparticles / immunology*
-
Humans
-
Meningococcal Infections / microbiology
-
Meningococcal Infections / prevention & control*
-
Meningococcal Vaccines / immunology*
-
Neisseria meningitidis, Serogroup B / genetics
-
Neisseria meningitidis, Serogroup B / immunology*
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
Serum Bactericidal Antibody Assay
Substances
-
Antibodies, Bacterial
-
Antigens, Bacterial
-
Meningococcal Vaccines
-
Recombinant Proteins